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Chapter 1 
 
Introduction 
1.1 Bronchopulmonary dysplasia 
 
Bronchopulmonary dysplasia (BPD), also referred to as neonatal chronic lung 
disease, is a chronic pulmonary disorder of infants that are prematurely born with 
very low birth weight. Bronchopulmonary dysplasia is characterized by dysregulated 
lung development and may lead to a number of complications. Depending on the 
severity of the disease, complications include recurrent pulmonary infections1, 
pulmonary hypertension2, poor growth3, impaired neurological development4 and 
death. Bronchopulmonary dysplasia is the primary severe complication of preterm 
birth5, having been first described in 1967 by W.H. Northway6, and ever since has 
been noted to be a major cause of morbidity in neonatal intensive care units. 
Improved perinatal care has led to a shift in the histopathological presentation of the 
disease: the “classic” or “old” BPD that is characterized by extensive inflammatory 
changes in the lung is rarely seen today. It has been replaced by the milder “new” 
BPD that is characterized largely by decreased alveolar septation and an arrest of 
late lung development7, 8.  
Neonates born with infant respiratory distress syndrome (IRDS) are at increased risk 
for developing BPD. Severe cases of IRDS require endotracheal intubation with 
positive-pressure ventilation and high levels of supplemental oxygen in order to 
maintain an acceptable blood oxygen-saturation. These supportive procedures lead 
to lung injury resulting in BPD9. Further risk factors include congenital heart 
disease10, antenatal infections, like chorioamnionitis11, and postnatal respiratory 
infections with CMV and Ureaplasma12. 
1.1.1 Clinical presentation and diagnosis 
The clinical symptoms of BPD are relatively non-specific and consist of cyanosis, 
chronic cough, rapid breathing and shortness of breath. Helpful measures that 
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support the diagnosis of BPD include blood-oxygen levels, which may reveal 
hypoxemia and hypercarbia; and chest imaging13, which may demonstrate 
emphysema as well as atelectasis. Bronchopulmonary dysplasia is typically 
suspected when a ventilated neonate can not be weaned from the supportive         
O2-therapy. According to a National Heart, Lung and Blood Institute workshop in 
20012, diagnostic criteria include oxygen-requirement of infants at a certain postnatal 
day. Bronchopulmonary dysplasia is subdivided into mild, moderate and severe BPD 
depending on the amount of oxygen required and on the gestational age of the 
newborn (Table 1). 
 
Table 1. Diagnostic criteria* and categorization of the severity of BPD (Modified from Jobe et 
al. 2001).  
<32 wk Gestational age†  ≥32 wk Gestational age‡ Diagnosis 
Breathing room air at 36 wk 
PMA or discharge, 
whichever comes first 
Breathing room air by 56 
days postnatal age or 
discharge, whichever comes 
first 
Mild BPD 
Need for <30% O2 at 36 wk 
PMA or discharge, 
whichever comes first 
Need for <30% O2 at 56 
days postnatal age or 
discharge, whichever comes 
first 
Moderate BPD 
Need for ≥30% O2, positive 
pressure, or both at 35 wk 
PMA or discharge, 
whichever comes first 
Need for ≥30% O2, positive 
pressure, or both at 56 days 
postnatal age or discharge, 
whichever comes first 
Severe BPD 
*These criteria are in addition to the baseline requirement of >21% O2 for at least 28 days. 
†Assessed at 36 wk postmenstrual age (PMA).                                                                                                    
‡Assessed at age 29 to 55 days.  
PMA = Post menstrual age, wk = Weeks. 
 
However, there are no accepted standards for supplemental oxygen administration 
which sets limitations on the use of supplemental oxygen as a criterion for BPD 
diagnosis. In order to overcome this problem, a physiological definition of BPD was 
established14. According to this definition, at 36 ± 1 weeks PMA, infants treated with 
positive pressure support, or supplemental oxygen concentrations of >30% and 
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oxygen saturations of 90-96% were diagnosed with BPD without additional testing. 
Infants receiving ≤30% oxygen or oxygen >30% with saturations >96% underwent a 
timed, stepwise reduction to room air with continuous observation and oxygen-
saturation monitoring.  “No BPD” was defined by oxygen-saturations ≥90% under  
room air for 30 minutes. “BPD” was defined by oxygen-saturations <90%. This new 
definition led to a reduction of the overall rate of BPD, and reduced the variation in 
the rate of BPD among centers. 
1.1.2 Epidemiology  
Owing to improved prenatal care in high risk patients, the clinical and pathological 
features of BPD have changed in recent years. Moreover, diagnostic criteria used to 
define BPD have been changing constantly with the changing nature of the disease. 
This complicates the monitoring of the incidence of BPD. Clearly the incidence of 
BPD decreases with advanced gestational age of the neonates. The disease rarely 
occurs beyond 32 weeks gestational age15. 
A study from 200116 reports an oxygen-dependence of 23% at 36 weeks among 
infants with a birth weight less than 1500 g. In 2003, another study17 demonstrated 
an oxygen-dependence of 53.2% at 36 weeks among infants born before 28 weeks 
gestational age. This points out that improved medical care does not, as one might 
expect, lead to a decrease in the incidence of BPD. Conversely, the use of antenatal 
glucocorticoids, postnatal surfactant treatment, and advanced respiratory and 
nutritional support in modern medicine may even lead to an increase in BPD 
incidence. Even the smallest premature infants now have a chance of survival due to 
these supportive measures. Yet, these infants are highly susceptible to lung damage 
through high pressure mechanical ventilation and oxygen toxicity maintaining a high, 
or possibly even increasing the incidence of BPD. 
1.1.3 Lung development and the pathogenesis of BPD 
Lung development is a lengthy process starting around the third week of the 
embryonic period and is completed in childhood at approximately 2-3 years of age, 
when the adult number of alveoli is reached. However, the size and surface area may 
increase until after adolescence18. At the end of the canalicular stage, between 
weeks 16 and 24 (Fig. 1), independent respiration is possible, however, survival rates 
of infants born at this stage of lung development are low. In the following saccular 
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stage, between week 24 and birth, the airspaces expand and surfactant is produced 
by pneumocytes. During this period, newborns have a much higher chance of 
survival. However, due to still markedly underdeveloped lungs early in this period, 
respiratory support of the newborns is often necessary. Positive pressure ventilation 
with oxygen-rich gas can cause chronic injury to the developing lung and is a major 
risk factor in the pathogenesis of BPD19. The ventilation disrupts critical signaling 
pathways, which results in failed formation of the alveoli20 and the pulmonary 
vasculature21, 22, 23, a decrease in alveolarization and, hence, a smaller gas-exchange 
surface in the lung.  
 
 
Embryonic 
period 
Fetal period 
 
2     4     6     8     10     12     14     16     18     20     22     24     26     28     30     32     36     38     40   
Weeks 
        - formation of major airways           - last generations of            - expansion of airspaces     - secondary 
                 the lung periphery            septation 
        - formation of bronchial tree           - epithelial             - surfactant detectable in 
                                                                            differentiation               amnionic fluid 
        - birth of the acinus            - air-blood barrier                
Organogenesis Differentiation 
 
Figure 1. The stages of human lung development and their features (modified from 
www.embryology.ch).  
 
pseudoglandular 
embryonic 
canalicular 
saccular 
alveolar 
surfactant 
 
 
birth 
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Extensive research has been invested to understand the mechanism of how oxygen 
might contribute to chronic inflammation and injury in the neonatal lungs. For 
example, in a mouse model of chronic exposure to hyperoxia, high oxygen 
supplementation (85%) led to a detectable increase in the expression of pro-
inflammatory cytokines and a decrease in cell proliferation24. 
However, understanding of the pathomechanisms underlying the pronounced arrest 
of alveolar septation is incomplete. To date, there are several publications that hint at 
a key role of lung extracellular matrix (ECM) metabolism in the development of BPD. 
Specifically, an incompletely understood dysregulation of collagen-25 and elastin 
metabolism26,27 leads to a disturbed pulmonary ECM architecture. 
 
 
1.2 Extracellular matrix and the developing lung 
 
The ECM, by definition being any material part of a tissue that is not part of a cell, is 
the defining feature of connective tissue. The ECM consists of glycoproteins such as 
collagen (the most abundant ECM protein in animals), fibrin, elastin, fibronectin and 
laminin. Moreover, the ECM contains minerals such as hydroxyapatite, and water. 
The ECM  functions mainly as a support and anchorage substrate for cells, as a local 
depot for a wide range of growth factors, as a regulator of intercellular communication 
and separates different tissues from each other.  
The ECM controls cellular growth, migration and differentiation in the developing 
lung. In turn, a variety of peptides, cytokines and growth factors, which are secreted 
from pulmonary cells, regulate gene expression, RNA processing and the translation 
of pulmonary ECM proteins28. The ECM proteins are crucial for proper branching of 
airways and alveolarization in the developing lung29. The ECM constituents are 
discharged from the cell for anchoring or communication, or serve as membrane 
receptors. The metabolism of ECM proteins, possibly including posttranslational 
modifications, is affected by changes in the cellular biochemical environment, such 
as changes in oxygen concentration30.  
Normal lung development follows a genetically programmed pattern and is 
dependent on the undisturbed interaction between cells and the ECM. During late 
lung development, primarily in the postnatal period, the lung gas exchange surface is 
expanded. This branching of airways is, in part, directed by the interaction of the 
epithelium with the underlying splanchnic mesoderm. Growth factors such as 
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fibroblast growth factor (FGF)31, transforming growth factor (TGF)-β32 and bone 
morphogenetic protein (BMP)33 are implicated in the growth and differentiation of the  
lung airway epithelium into the multiple cell lineages required for postnatal respiratory 
tract formation. These growth factors are engaged in multiple pathways that act 
individually and as a network. Minor disruptions to this process may affect the 
immature lung, leading to a pronounced decrease in lung function. 
A better understanding of the intercellular communication, the intracellular signaling 
pathways and extracellular metabolic pathways is essential to gain insight into the 
pathomechanisms of BPD. 
 
 
1.3 Collagen processing in ECM assembly 
 
Collagen synthesis starts at the gene level. Each collagen type has a unique primary 
sequence and, therefore, a specific mRNA. After mRNA processing, the translation, 
as with most other proteins that are destined for the ECM, takes place at the rough 
endoplasmatic reticulum (rER). The translation product, the preprocollagen (also 
called α-chains), contain a signal peptide, and is translocated into the lumen of the 
rER. Preprocollagen has an unusual sequence: approximately every third amino acid 
is glycine and about 17% of all amino acid residues are proline residues. Relative to 
the location of glycine emerges another important amino acid: lysine. Inside the rER 
lumen, proline and lysine residues undergo hydroxylation by prolyl hydroxylases or 
lysyl hydroxylases, respectively (Fig. 2). These reactions are vitamin C-dependent 
and represent a very important step in the posttranslational modification of collagen. 
Insufficient hydroxylation may lead to defective collagen molecules and damage ECM 
formation. Hydroxylysine residues are then glycosylated, where the triple helical 
structure can be formed. Alternatively the residues serve as anchorage points for 
covalent cross-links between the collagen molecules (this cross-link also occurs in 
other proteins with collagen-like domains)34. Hydroxyproline stabilizes the triple helix 
by forming hydrogen-bonds between the chains. After the so-called “procollagen” is 
secreted from the cell, the extension peptides from the termini of the molecule are 
removed by the metalloproteinases ADAMTS-2 (A disintegrin and metalloproteinase 
with thrombospondin motifs-2) and bone morphogenetic protein (BMP)-1. The 
cleaved extension peptides, in turn, are believed to reenter the cell and regulate 
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collagen synthesis via a feed-back mechanism35. Finally, the molecule resides in the 
extracellular space and is now called collagen. To form collagen fibrils and fibers 
which provide extraordinary strength to the mature collagen structures, a reaction 
catalyzed by lysyl oxidase is required36. Lysyl oxidase forms inter- and intra-cellular 
cross links within or between collagen fibers, which represents the most critical 
posttranslational modification. The ready-made collagen fibers can now establish, 
together with other proteins including elastin and fibronectin, the ECM.  
The fibers of the ECM, however, do not present a rigid structure. As described below, 
in Chapter 1.5, other enzymes, including transglutaminases, may enhance the 
number of cross links between proteins in the extracellular space, in order to further 
stabilize the ECM. 
 
 
 
 
 
Figure 2. The intra- and extracellular steps of collagen synthesis. 
 
ER = Endoplasmic reticulum, ADAMTS = A disintegrin and metalloproteinase with 
thrombospondin motifs, BMP = Bone morphogenetic protein 
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1.4 ECM remodeling and TGF-β signaling 
 
Several studies have investigated disturbed structural synthesis and production of 
ECM proteins in BPD. For example Thibeault et al.37 described an increase in 
interstitial collagen deposition caused by prolonged mechanical ventilation of 
premature infants. These collagen fibers, apart from an increase in quantity, were 
characterized as being “disorganized, tortuous, and thickened” (Fig. 3). 
 
 
  
 
Figure 3. En face sections through alveolar septal walls of two premature infants (taken from 
Thibeault et al.37). 
Left, Section of a 30-week-gestation control lung. There is a continuous mesh of fine and 
coarse collagen fibers connecting to the large fibers at the air sac mouth.  
Right, Section of a 24.4-week gestational age infant that died at 28.8 weeks post conception. 
The arrow points out a thickened, tortuous secondary fiber. The arrowhead points out 
secondary fibers uniting with a thick tertiary fiber. 
 
 
However, relatively few studies have addressed posttranslational modifications, 
stabilization and breakdown of ECM proteins. A connection between the 
pathogenesis of BPD and enhanced ECM cross-linking has already been suggested 
by Pierce et al.26 in 1997. In this study, an increase in desmosine, a marker of   
cross-linked elastin, as well as an increase in elastin production, was observed in the 
lungs of mechanically ventilated preterm lambs. In 2009, the expression of lysyl 
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oxidase, an enzyme important for ECM protein cross-linking, was found to be         
up-regulated in mice after exposure to a hyperoxic gas mixture. Likewise,               
up-regulation of lysyl oxidase expression was found in the lungs of infants that died 
with BPD or were at risk of developing BPD38. It was hypothesized that this might 
result in an “over-stabilization” of collagen and elastin molecules and, hence, of the 
ECM. Because TGF-β is believed to be a highly important growth factor in late lung 
development39 and in the pathogenesis of BPD40,41, the effect of TGF-β on lox gene 
(encoding lysyl oxidase) expression was examined in this study. Enhancement of lox 
gene expression in the developing mouse lung was observed to be partly driven by 
abnormal TGF-β signaling. As early as in 200642 hyperoxia was shown to potentiate 
TGF-β signaling in lung fibroblasts which, in turn, enhanced the production of a 
number of ECM proteins, including the α1-subunit of type I collagen, tissue inhibitor of 
metalloproteinase-1, tropoelastin, and tenascin-C.  
Given these data and the variety of enzymes responsible for ECM remodeling, it is 
highly promising to look at other types and families of ECM cross-linking enzymes: 
therefore, in the present study, lysyl hydroxylase and transglutaminase expression 
was examined with respect to TGF-β stimulation, and the impact of normobaric 
hyperoxia in an animal model. 
 
 
1.5 ECM cross-linking enzymes 
 
1.5.1 Lysyl Hydroxylases  
Lysyl hydroxylases are enzymes that catalyze the vitamin C-dependent hydroxylation 
of lysine residues in collagen and collagen-like proteins, resulting in the formation of 
a hydroxylysine residue (Fig. 4).  
This occurs inside the rER prior to triple-helix formation. These hydroxylated lysine 
residues are later either glycosylated or required for the formation of covalent and 
irreversible cross-links between collagenous molecules and, hence, are crucial for 
the maturation of the ECM.  
The lysyl hydroxylases, which are also referred to as procollagen-lysine,                    
2-oxoglutarate 5-dioxygenase (Plod) enzymes, occur as three different enzymes, 
encoded by three different genes in human, rat and mouse tissue: Plod1, Plod2 and 
Plod3.  
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Figure 4. Hydroxylation reaction of a lysine residue in a collagenous sequence catalyzed by 
lysyl hydroxylase. One oxygen molecule is needed to hydroxylate the lysine residue and to 
decarboxylate 2-oxoglutarate. The CO2 is liberated by this reaction (taken from Puistola et 
al.)43. 
 
 
 
The Plod1 gene product, the lysyl hydroxylase 1, is responsible for lysyl hydroxylation 
in the helical part of collagen type I. Mutations in the PLOD1 gene lead to a heritable 
disorder of the connective tissue, characterized by joint hypermobility and skin 
fragility and hyperextensibility: the Ehlers-Danlos Syndrome Type VI (EDS VI)44.  
Plod2 exists in two alternatively-spliced forms. The shorter isoform (Plod2a) is, so far, 
only known to be expressed in the human kidney, spleen, liver and placenta. Plod2b, 
the longer isoform, demonstrated its significance in ECM disorders in a study from 
200445, where increased formation of pyridinoline cross-links was found to be a 
consequence of increased expression of Plod2b. The pyridinoline cross-link is the 
product of a lysyl-oxidase catalyzed reaction and is elevated in a variety of fibrotic 
disorders including systemic scleroderma.  Also, Plod2 exhibits an increased  
transcriptional activity in systemic sclerosis46, which suggests a possible connection 
between elevated levels of Plod2, increased pyridinoline cross-linking and fibrotic 
tissue formation. 
A mutation in the Plod2 gene results in Bruck’s syndrome, a recessively inherited 
ECM disorder characterized by skeletal changes similar to osteogenesis imperfecta 
and contractures of the large joints47.  
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The third member, Plod3, in addition to playing a role in lysyl hydroxylation, 
possesses glucosyltransferase and galactosyltransferase activities48. Moreover, 
Plod3 has an important role in the dynamic remodeling of the ECM49, as Plod3 is 
localized both intra- and extra-cellularly. In the extracellular space, Plod3 can adjust 
the amount of hydroxylysine and hydroxylysine-linked carbohydrates of extracellular 
proteins50. In Plod3 knockout mice, collagen IV synthesis is impaired, which results in 
disturbed basement membrane formation and, thus, abnormal embryonic 
development and embryonic death51. 
All Plod genes have been described to be widely expressed during mouse 
embryogenesis (Plod1 being the most highly expressed) with similar expression 
patterns and tissue location52. In adult cells, the Plod distribution profiles become 
more specialized. The Plod1 and Plod2 members are mainly localized inside the rER 
lumen, whereas Plod3, depending on the tissue-type, can be present inside as well 
as outside the cell. However, in lung tissue, where all three isoforms are highly 
expressed, Plods were, by light microscopy, localized only intracellularly and 
expression was very cell specific: Plod2 in smooth muscle bundles of the 
bronchioles, and Plod3 in type II pneumocytes53. 
Based on a study by Alejandre-Alcázar et al.42 that demonstrated that hyperoxia 
induced TGF-β, and TGF-β, in turn, up-regulated several ECM proteins, one could 
hypothesize that TGF-β might also induce Plod genes. Yet, there is little information 
available in the literature about the possible influence of TGF-β on lysyl hydroxylase 
expression. In human osteoblasts, lysyl hydroxylation in collagen, particularly in the 
collagen α2 chain, was decreased by TGF-β1. Moreover lysyl hydroxylase mRNA 
levels were reduced, whereas mRNAs for collagen α-chains were stimulated by TGF-
β54. Similar tendencies were observed in adipose tissue-derived mesenchymal stem 
cells, where TGF-β1 down-regulated the expression of Plod355. However, in 2005, a 
study found that several cytokines, including all three isoforms of TGF-β, influenced 
the collagen cross-linking pathway by up-regulating Plod2b mRNA levels as well as 
the abundance of the pyridinoline cross-link, which is increased in several fibrotic 
disorders56. This up-regulation of Plod2b expression, observed in skin fibroblasts, 
was higher, even relatively to the up-regulation of the expression of the collagen α2 
chain, suggesting more cross-links per collagen molecule.  
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1.5.2 Transglutaminases 
The transglutaminase (Tgm) family of enzymes is a ubiquitously expressed group of 
intra- and extra-cellular enzymes that catalyze a calcium-dependent posttranslational 
modification reaction: the transamidation of glutamine residues (Fig. 5).  
 
 
 
Figure 5. The transglutaminase-catalyzed reaction between the γ-carboxamide group of a 
peptide-bound glutamine and the primary amine group of a peptide-bound lysine. The 
product is the γ-glutamyl-ε-lysine cross-link, levels of which are increased in many fibrotic 
disorders (taken from Chen et al.57).  
 
 
This results in the formation of γ-glutamyl-ε-lysine cross-links, which are highly 
resistant to proteolysis, and stabilize the ECM proteins in a variety of tissues against 
chemical, enzymatic or mechanical breakdown.  
There are nine different tranglutaminase-genes58 that have been identified in 
mammals (Table 2). Yet, only eight of these genes encode active enzymes. 
Transglutaminase-mediated cross-linking is believed to be involved in the 
pathogenesis of a variety of diseases such as lamellar ichthyosis, psoriasis (for 
Tgm1) Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and 
cardiovascular diseases59,60 (for Tgm2). 
Transglutaminase 1, although also called keratinocyte transglutaminase, has also 
been described to be expressed in lung tissue, more specifically in normal bronchial 
epithelium61. The role of Tgm1 has been extensively studied in the epidermis where it 
is involved in the maintenance of skin tissue integrity and impermeability as well as in 
cell envelope formation in the differentiation of keratinocytes62. Transglutaminase 1 
activity in keratinocytes is primarily membrane-bound63. The Tgm1 is believed to be a 
marker for squamous differentiation and to be useful in evaluating the degree of 
differentiation in benign and malignant oral epithelial proliferation64. However, little is 
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known about Tgm1 function in the lung, making it an interesting target for 
investigation in the context of ECM remodeling disturbances in BPD.  
 
Table 2. The mammalian transglutaminase family and its distribution in tissues and cell-
components. (Modified from Esposito et al.65). 
             
Name Synonyms Tissue Location 
 
Tgm1 Keratinocyte Tgm, 
TGK 
Epithelia Cytosolic, membrane 
Tgm2 Tissue Tgm, TGC Ubiquitous Cytosolic, nuclear, 
extracellular 
Tgm3 Epidermal Tgm, TGE Epithelia Cytosolic 
Tgm4 Prostate Tgm, TGP Prostate Extracellular 
Tgm5 TGX Epithelia Cytosolic 
Tgm6 TGY Unknown Unknown 
Tgm7 TGZ Ubiquitous Unknown 
FXIII Factor XIIIA, fibrin 
stabilizing factor 
Blood plasma, 
platelets 
Extracellular 
Band 4.2 Erythrocyte protein 
band 4.2 
Erythrocytes Membrane 
 
 
Transglutaminase 2, in contrast, is an enzyme that is expressed in a large variety of 
tissues and occurs in an intracellular as well as in an extracellular form and, hence, 
post-translationally modifies intra- and extra-cellular proteins. The Tgm2 is involved in 
cell death and differentiation, matrix stabilization and serves as an adhesion protein. 
The extracellular Tgm2 is secreted, usually in very small amounts, from the cell into 
the extracellular space, where it is implicated in the cell-ECM interactions by cross-
linking matrix proteins66. Many proteins that are needed for stabilization and 
remodeling of the ECM, such as collagen, fibronectin, fibrinogen/fibrin, vitronectin, 
osteopontin, laminin and nidogen, have been identified as substrates of Tgm262. 
Stress on a cell often leads to an up-regulation of Tgm2 and further secretion of the 
enzyme into the matrix. Furthermore, intracellular Tgm2 leaks from dying cells into 
the extra cellular space, resulting in massive matrix cross-linking and scar tissue 
formation. Tgm2 expression and, thus, the abundance of the γ-glutamyl-ε-lysine 
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crosslink, are enhanced in all fibrotic disorders that are characterized by excessive 
scar tissue formation, including lung fibrosis67, 68. 
Transglutaminase 2 is further presumed to be involved in chronic inflammatory 
diseases by enhancement of TGF-β activation in the ECM69, 70. Elevated levels of 
TGF-β can lead to increased matrix deposition and, additionally, have been 
described to up-regulate pulmonary TGM2 expression71, both  possibly resulting in 
over-stabilization of the ECM. These findings suggest a complex, mutual control 
mechanism between Tgm2 and TGF- β.   
Another interesting feature of Tgm2 was observed during lung development. In 
newborn rats, Tgm2 enzyme activity was detected before term, whereas the γ-
glutamyl-ε-lysine crosslink was detected for the first time between postnatal days 10 
and 1972. In the larger airways and vessels of the lung, where maturation is known to 
occur earlier, the γ-glutamyl-ε-lysine cross-link as well as the extracellular Tgm2 
appeared at the end of the first postnatal week. It was concluded that Tgm2 presence 
and activity could be used as a marker for postnatal lung maturation. The irreversible 
crosslinking is believed to be enhanced towards the end of lung-development in 
order to stabilize the final structure of the organ. Irregularities in the expression of 
Tgm2, like premature enzyme upregulation, may therefore result in over-stabilization 
and impaired remodeling of the ECM and early termination of lung organogenesis.  
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Chapter 2 
Hypothesis and Aims 
Bronchopulmonary dysplasia is a dangerous complication of prematurity. Although 
several causes and risk factors for BPD have been identified, exact knowledge about 
the pathogenesis of BPD is still lacking. Many publications assume disturbances in 
pulmonary ECM metabolism as one of the causes that lead to impaired lung 
development and respiratory function. This is thought to be caused by abnormal 
cytokine signaling. Dysregulation of ECM cross-linking enzymes as well as TGF-β 
signaling has been demonstrated by several studies. However, little is known about 
which cross-linking enzymes are abnormally active or expressed in BPD. In this 
context, the expression of lysyl hydroxylases and tranglutaminases was examined 
using a chronic hyperoxia mouse model of BPD. Moreover, signaling pathways that 
possibly regulate these cross-linking enzymes are poorly investigated. Here, the 
effect of TGF-β and hyperoxia on the expression of lysyl hydroxylases and 
tranglutaminases in different cell lines was studied. 
 
 
2.1 Hypothesis 
Based on the rationale outlined above, it was hypothesized, that 
• The expression of lysyl hydroxylases and transglutaminases is altered during 
pathological late lung development.  
• Dysregulation of lysyl hydroxylases and transglutaminases is triggered by 
hyperoxia and/or the growth factor TGF-β. 
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2.2 Aims 
Hence, the aims of the study were 
• To determine whether the expression of lysyl hydroxylases and 
transglutaminases change in a mouse model of BPD.  
• To investigate whether the expression of lysyl hydroxylases and 
transglutaminases is influenced by hyperoxia and/or TGF-β. 
- 25 - 
Chapter 3 
 
Materials and Methods 
3.1 Materials 
3.1.1 Technical equipment and manufacturer 
Equipment                 Manufacturer 
Developing machine; X Omat 2000 Kodak, USA 
Electrophoresis chambers Bio-Rad, USA 
Film cassette Sigma-Aldrich, Germany 
Filter Tip FT: 10, 20, 100, 200, 1000 Greiner Bio-One, Germany 
Freezer  -20 °C Bosch, Germany 
Freezer  -40 °C Kryotec, Germany 
Freezer  -80 °C Heraeus, Germany 
Fridge +4 °C  Bosch, Germany 
Gel blotting paper 70 x 100 mm Bioscience, Germany 
Glass bottles: 250, 500, 1000 ml Fisher, Germany 
Mini spin centrifuge Eppendorf, Germany 
Multifuge centrifuge, 3 s-R Heraeus, Germany 
Nanodrop
 ® 
 Peqlab, Germany 
PCR-thermocycler MJ Research, USA 
PCR-tubes (0.2 ml) Applied Biosystems, USA 
Pipetboy Eppendorf, Germany 
Pipetmans: P10, P20, P100, P200, P1000 Gilson, France 
Quantity One software Bio-Rad, Germany 
Radiographic film X-Omat LS Sigma- Aldrich, Germany 
Serological pipette: 5, 10, 25, 50 ml  Falcon, USA 
Single-use syringe Braun, Germany 
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Test tubes: 15, 50 ml BD Biosciences, USA 
Trans blot transfer membrane (0.2 µm) Bio-Rad, USA 
Vortex machine Eppendorf, Germany 
Vacuum centrifuge Eppendorf, Germany 
Western blot chambers: 
                        Mini Trans-Blot  
                        Mini-Protean 3 Cell 
 
Bio-Rad, USA  
Bio-Rad, USA 
 
3.1.2 Reagents and source of supply 
Reagents             Source of supply        
Acetone Roth, Germany 
Acrylamide solution, Rotiphorese Gel 30 Roth, Germany 
Agarose Invitrogen, UK 
β-mercaptoethanol Sigma-Aldrich, Germany 
Bromophenol blue Sigma-Aldrich, Germany 
DNA Ladder (1 kb) Promega, USA 
Dulbecco´s phosphate buffered saline 10× PAA Laboratories, Austria 
Dulbecco´s phosphate buffered saline 1× PAA Laboratories, Austria 
Ethylendinitrilo-N, N, N',N'-tetra-acetic-acid (EDTA) Promega, USA 
Ethanol absolute Riedel-de Haën, Germany 
ECL Plus Western Blotting Detection System Amersham Bioscience, UK 
Ethidium bromide Roth, Germany 
Gel extraction kit Qiagen, Germany 
Glycine Roth, Germany 
Magnesium sulfate Sigma-Aldrich, Germany 
Methanol Fluka, Germany 
N,N,N',N'-tetramethyl-ethane-1,2-diamine (TEMED) Bio-Rad, USA 
Oligo(dT)15 primer Promega, USA 
PCR Nucleotide Mix Promega, USA 
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2-Propanol Merck, Germany 
QIAprep Spin Miniprep Kit Qiagen, Germany 
Quick StartTM Bradford Dye Reagent Bio-Rad, USA 
RNAsin inhibitor Promega, Germany 
RNeasy Midi Kit Qiagen, Germany 
Smooth muscle cell medium 2  Promocell, Germany 
SuperSignal® West Pico Chemiluminescent Substrate Pierce, USA 
Tris Roth, Germany 
Trypsin/EDTA Gibco BRL, Germany 
Tween 20 Sigma-Aldrich, Germany 
 
3.2 Methods 
3.2.1 Animal and tissue treatment 
All animal procedures were approved by the animal ethics authority of the 
government of the state of Hessen (Regierungspräsidium Giessen II25.3–19c20 –
15(1) GI20/10-Nr.22/2000). 
A mouse model of chronic exposure to hyperoxia 
Mice are excellent animals to study pulmonary diseases of prematurity. Mouse pups 
are born in the saccular stage of lung development, which mimics the pulmonary 
conditions in premature human infants that are born between the 24th and 36th week 
of gestational age. 
Newborn - as well as adult - C57BL/6J mice were maintained in humidity- and 
temperature-controlled rooms. Mice were allowed food and water ad libitum and were 
maintained on a 12h-12h light-dark cycle. Neonates from four to eight litters, which 
were born within a maximum of three hours apart, were pooled on their first day of 
birth (P1). After randomizing pups to nursing dams, these pups were separated into 
two equally sized groups: 50% remained in room air [21% (vol/vol) O2], while the 
other 50% were maintained in 85% O2. In order to prevent oxygen toxicity to the 
nursing dams, dams were exchanged between hyperoxic and normoxic conditions 
every 24 h. Pups were housed in 90 × 42 × 38 cm Plexiglas chambers that were 
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ventilated continuously at a flow rate of 3.5 l/min. A Miniox II monitor (Catalyst 
Research, Owing Mills, MD) was used to control oxygen concentration inside the 
chambers at all times. To measure dynamic compliance, the volume-pressure 
compliance method in anesthetized mice, as described previously73, was utilized. At 
postnatal days 1, 7, 14, 21 and 28 mice were killed for analysis. These four weeks 
after birth span the period of late lung development in mice. 
Processing of lung tissue 
Mice were killed by an intraperitoneal injection of sodium pentobarbital. After opening 
the aorta, mice bled out and the heart and lungs could be excised en bloc. The lungs 
were pressure-fixed overnight at 20 cmH2O with 4% (mass/vol) paraformaldehyde in 
phosphate-buffered saline (PBS; 20 mM Tris-Cl, 137 mM NaCl, pH 7.6), and then cut 
into 3-µm sections and mounted on glass slides.  
 
3.2.2 Human tissue 
The Human Subjects Review Committees of the Erasmus University Medical Centre 
and the University of Giessen Lung Center approved the utilization of human 
material. The neonatal lung tissue used in this work accrued from archived autopsy 
material at the Erasmus University Medical Centre and the University of Giessen 
Lung Center.  
 
3.2.3 Cell culture  
Mouse NIH/3T3 fibroblast-like cells (American Type Culture Collection), primary 
human pulmonary artery smooth muscle cells (paSMC) (Promocell) and cells from 
the human keratinocyte cell-line (HaCaT) (Lonza) were cultured and assessed for 
dysregulation of ECM enzyme expression under hyperoxic condition and/or TGF-β 
stimulation. The cells were maintained under 21% O2 or 85% O2 for 24 h, prior to 
stimulation with TGF-β1 (2 ng/ml) for a further 24 h. Gas tension in the culture media 
was monitored daily. 
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3.2.4 RNA isolation 
The RNA derived from the cell cultures and isolation was accomplished following the 
manufacturer’s instructions provided with the RNeasy Midi Kit. 
 
3.2.5 Assessment of RNA concentration 
For assessment of the concentration and quality of the RNA isolated from the cell 
lines, 1.5 µl from the sample RNA was inserted into a Nanodrop® spectrophotometer. 
Absorbance was measured at 260 nm. 
 
3.2.6 Reverse transcription reaction 
The reverse transcriptase polymerase chain reaction, abbreviated as RT-PCR, is a 
technique where a RNA strand is reverse transcribed into its complementary DNA 
(cDNA) (in the RT step) and then amplified using the PCR. The RT-step is catalyzed 
by the enzyme reverse trancriptase (RT). The PCR is catalyzed by DNA polymerase. 
In this reaction, cDNA is synthesized using a single strand of RNA as a template.   
The RT reaction was performed using the Improm-II Reverse Transcriptase kit 
purchased from Promega (USA). 
The RT reaction was carried out by assembling a mixture composed of 500 ng of 
RNA from the experimental lungs and 4 µl of oligo(dT)15 (100 µg/ml) to prime the 
reaction. This was diluted with RNAse-free water to 10 µl final volume. This mixture 
was heated in a thick-walled PCR tube, at 70 °C for 5 min. This process denatures 
the double-stranded RNA into single strands and, hence, provides access for the 
primers to bind precisely to the polyA tail of the mRNA strand. Immediately after, the 
PCR tube was chilled on an ice medium for at least 5 min. Thereafter the RT-Mix 
(Table 3) reaction components were added.  
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Table 3: Components of the RT-Mix (Promega). 
Reaction components Volume (µl) Final concentration 
ImProm-II™ 5× Reaction 
Buffer 
4.0 1× 
MgCl2 (25 mM)  4.8 6 mM 
dNTP Mix (10 mM) 1.0 0.5 mM 
RNasin® Ribonuclease 
Inhib. ImProm-II™ 
1.0 1 unit 
Reverse transcriptase 1.0 1 unit 
RNAse free water 3.2 Not applicable 
Total Volume 15.0 - 
 
 
After the reaction components were mixed by pipetting, the tubes were placed in the 
PCR machine, where the RT-PCR program was carried out. This program consists of 
three steps: the first step causes the linearization of the RNA. For this purpose the 
mix was warmed up to 25 °C for 5 min. For the next step, the cDNA synthesis, the 
tube was heated to 42 °C. During the third and last step, the sample was cooled 
down to 4 °C. This so-called chilling was carried out over night. 
For cDNA synthesis from the mRNA isolated from cell-cultures, the Sensiscript® 
Reverse Transcriptase Kit from Qiagen, which can reverse-transcribe less mRNA, 
was used. The step of RNA denaturation in RNAse free water was performed at      
65 °C for 5 min. Again the samples were chilled on ice and then mixed with the     
RT-Mix as described in Table 4. 
The cDNA produced by these reactions was either used immediately for amplification 
via PCR or was stored in a freezer at -20 °C for later use. 
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Table 4. The Sensiscript RT-Mix (Qiagen). 
 
Reaction Components Volume (µl) Final Concentration 
10× Buffer RT 2.0  1× 
dNTP Mix (5 mM each dNTP) 2.0  0.5 mM each dNTP 
Oligo-dT primer (10 µM) 2.0  1 µM 
RNAse inhibitor (10 u/µl) 1.0  10 u (per reaction) 
Sensiscript Reverse Transcriptase 1.0  
RNAse-free water Variable not applicable 
   
Template RNA Variable <50 ng (per reaction) 
Total volume 20.0  - 
 
 
3.2.7 Semi quantitative polymerase chain reaction 
The polymerase chain reaction (PCR) is an enzymatic reaction used to amplify 
strands of DNA, in this case cDNA, which were generated from mRNA in the RT 
reaction. The PCR reaction was used to assess gene expression by exponentially 
amplifying the DNA sequence of interest. The enzyme used for this reaction is a 
special heat-resistant DNA polymerase, the Taq polymerase. Each PCR-reaction 
consists of three steps. 
1. Denaturation: The double stranded DNA in the sample is being denatured by  
heat. Hydrogen bonds are broken, which results in single stranded DNA 
molecules. 
2.  Annealing: The primers in the sample bind to the appropriate sites on the 
single-stranded DNA. 
3. Elongation: The Taq polymerase synthesizes a new DNA strand 
complementary to the template. 
Each reaction, or cycle, doubles the amount of DNA in the sample. Thus, DNA 
strands multiply exponentially with the cycle number of the PCR reaction. 
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3.2.7.1.1 Semi quantitative PCR protocol 
The polymerase used in this reaction was GoTaq®Flexi DNA Polymerase from 
Promega, in a final volume 25 µl. Apart from the DNA and the polymerase, a PCR 
mix with the components (listed in Table 5) was prepared.  
An example of thermal cycling conditions for PCR amplification is presented in   
Table 6; however, the annealing temperature may vary with different primers (the 
primers used in the PCR reaction and the different annealing temperatures are listed 
in Table 7).  
 
 
Table 5. Semiquantitative PCR mix 
 
Components Volume (µl) Final concentration 
5x Green GoTaq Flexi Buffer 5.00  1x 
MgCl2 solution (25 mM) 2.00 2 mM 
PCR Nucleotide Mix (10 mM) 0.50 0.2 mM each dNTP 
Upstream primer 0.50 0.2 µM 
Downstream primer 0.50 0.2 µM 
GoTaq Polymerase (5 u/µl) 0.25 1.25 u  (per reaction) 
Template DNA ~1-2 µl <0.25 µg/25 µl 
Nuclease-free water up to 25.00 - 
Total Volume ~35  - 
 
 
Again the components were combined and mixed by pipetting, before placing the 
tubes in the PCR machine. 
The three crucial steps denaturation, annealing and elongation (extension) are 
repeated, depending how many copies are needed. Each cycle means a doubling of 
the amount of DNA that was in the tube at the beginning of the new cycle. This 
means an exponential increase of DNA in the sample with the number of cycles.  
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Table 6. PCR program for thermal cycling conditions for DNA amplification 
Step Temperature (°C) Time Number of cycles 
Initial denaturation 95  2 min 1 cycle 
Denaturation 95  0.5-1 min 
Annealing 42-65  0.5-1 min 
Extension 72  1 min/kb 
 
25-35 cycles 
Final extension 72  5 min 1 cycle 
Soak 4  Infinite 1 cycle 
 
 
Table 7. List of primers for mouse and human genes 
Gene 
name 
Forward Primer                   
from 5´ to 3´ 
Reverse Primer                 
from 5´ to 3´ 
Annealing 
Temperature 
(°C) 
Mouse    
Plod1 CAGGAGGTGTTCATGTTCCT CTCATGATAGTGTGTGAGCC 63 
Plod2 AGTCGAGCAGCCTTGTCCAG TCCTTCGTGCAAATGTGTGA 63 
Plod3 GAGAACAGTACATTCACGAG GACACCATGATGTATCGAGT 63 
Tgm1 TCTACATGAAGTATGACACA CACCTCGATATGCCATAGGT 57 
Tgm2 GAGCGAGATGATCTGGAACT ACTTCAGCTTGTCACACTGG 60 
Hspa8 TTACCCGTCCCCGATTTGAAGAAC TGTGTCTGCTTGGTAGGAATGG 58 
Human    
PLOD1 ACATCCACCAGAACTACACC GGATCGACGAAGGAGACTGC 60 
PLOD2 CTGATGGATACTATGCACGA AAGACATCTGGACAGGGCTG 60 
PLOD3 GTGTTCTCGGGCAGTGACAC GATCACACAGTCGTAGCGCA 60 
TGM1 TGGTCTACATGAAGTACGAC GAGATGCCATAGGGATGGTC 63 
TGM2*(1) 
(2) 
GCAGCAGCCCCGTCTACGTG GCTCTCGAAGTTCACCACCA 
CAAGATCCCATTGTAGCTGA 
63 
63 
HSPA8 TTACCCGTCCCCGATTTGAAGAAC TGTGTCTGCTTGGTAGGAATGG 58 
* Two different reverse primers for the TGM2 gene have been described in human cells. Both       
were used in the present study.  
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The semiquantitative PCR was carried out using either mouse primers for whole lung 
tissue and mouse fibroblasts or human primers for human paSMC or human 
keratinocytes. All primers used are listed in Table 7. 
After the final extension, the sample was chilled down to 4 °C. Thereupon, the 
samples underwent analysis by gel electrophoresis or were stored at -20 °C.  
 
3.2.8 Gel electrophoresis 
Gel electrophoresis is used to separate nucleic acids or proteins, for example by size, 
physical structure or electric charge. 
 
3.2.8.1 DNA gel electrophoresis 
For DNA gel electrophoresis a 1% agarose gel was employed. The agarose powder 
was dissolved in 200 ml 1× Tris-acetate-EDTA (TAE) buffer (40 mM Tris-acetate, pH 
8.0, 1 mM EDTA, pH 8.0). To melt the agarose, the mixture was heated in the 
microwave. To later visualize the DNA in the gel, 0.5 µg/ml ethidium bromide was 
added to the liquid gel. Ethidium bromide intercalates between DNA bases and 
fluoresces under UV light, whereby it can be seen and documented. The signal 
intensity correlates with the amount of DNA in the gel and, hence, is interpreted as a 
function of amplicon abundance. After 10 min cooling at room temperature, the gel 
solution was poured into a casting frame. While the gel was still in liquid form, the 
teeth of a plastic comb were inserted to form the wells. After at least 30 min at room 
temperature, the gel set and the comb could be carefully removed. The gel was 
transferred to another tray with a positive and a negative electric pole. The tray was 
filled with 1× TAE buffer and the samples along with the loading dye (containing 
0.01% bromphenol blue, 40% glycerol in 1× TAE buffer) were loaded into the wells. 
The electrophoresis was performed by applying 100-120 V to the gel slab for 40-60 
min. Thereafter the gel was examined under an UV light (λ=257 nm) transluminator 
and the signal was documented with a Kodak 1D 3.5 camera for several different 
exposure times. 
 
3.2.8.2 Protein gel electrophoresis 
In order to separate out proteins in complex mixtures, a sodium dodecyl sulfate 
(SDS) poly acrylamide gel electrophoresis (PAGE) was performed. First, the 
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resolving (separating) gels had to be produced. The gel ingredients are listed in 
Table 8. The mixture was poured between two glass plates with spacers in between 
them. Isopropanol was layered on top of the gel solution to flatten the gel surface. 
Another gel, the stacking gel, the ingredients of which are listed in Table 9, was also 
poured between the glass plates on top of the resolving gel, in exchange for the 
isopropanol. A comb was placed into the stacking gel, while it was still in liquid form, 
to form the wells. Thereafter, the proteins extracted from mouse lung tissue were 
mixed with 2× loading dye buffer [100 mM Tris-Cl, pH 6.8, 200 mM DTT, 4% (vol/vol) 
SDS, 0.2% (vol/vol) bromphenol blue, 20% (vol/vol) glycerol, 9% β-mercaptoethanol] 
and denatured by heating to 95 °C for 10 min. The samples were loaded into the 
wells in the stacking gel, after having carefully removed the comb. The gel 
electrophoresis was run in 1× SDS-running buffer (25 mM Tris, 50 mM glycine, 0.1 % 
(vol/vol) SDS) for 1 h at 120 V.  
 
 
 
Table 8. Resolving gel ingredients, and the corresponding amounts needed for 40 ml 
(4 gels). 
 
Component Volume 
dH2O 15.9 ml 
30% Acrylamide 13.3 ml 
1.5 M Tris-HCl, pH 8.8 10.0 ml 
10% SDS 400 µl 
10% APS 400 µl 
TEMED 16 µl 
 APS = Ammonium persulfate 
SDS = Sodium dodecyl sulfate poly acrylamide                                                          
TEMED = N, N, N',N' tetramethyl-ethane-1,2-diamine 
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Table 9. Stacking gel ingredients, and the corresponding amounts needed for 20 ml 
(4 gels). 
 
Component Volume 
dH2O 13.6 ml 
30% Acrylamide 3.32 ml 
1.5 M Tris-HCl, pH 6.8 2.52 ml 
10% SDS 200 µl 
10% APS 200 µl 
TEMED 20 µl 
 APS = Ammonium persulfate 
SDS = Sodium dodecyl sulfate poly acrylamide                                                          
TEMED = N, N, N',N' tetramethyl-ethane-1,2-diamine 
 
 
 
3.2.9 Western blot analysis 
The western blot or immunoblot is a technique used to detect, visualize and quantify 
proteins on a membrane by identifying these proteins with specific antibodies. 
Following SDS-PAGE, the proteins that were separated in the gel were transferred 
on to a 0.25 µm nitrocellulose membrane: the membrane was placed on top of the 
gel, and filter paper placed on both sides to form a “sandwich” or stack. The entire 
stack was placed into a Bio-Rad chamber that contained blotting (transfer) buffer (25 
mM Tris base, 192 mM glycine, 20% methanol). An electric potential of 110 V was 
applied to the chamber for 1 h. The electric current that was generated transferred 
the proteins from the gel to the nitrocellulose membrane. 
After blotting, the membranes were placed in blocking solution (5% non-fat dry milk 
powder in PBS, 0.1% (vol/vol) Tween-20) for 1 h at room temperature. The blocking 
buffer was discarded and membranes were then incubated in blocking buffer 
containing the respective primary antibody against the target protein (primary and 
secondary antibodies and dilutions are listed in Table 10).  
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Table 10: Primary and secondary antibodies used in immunoblot-analysis. 
 
Antibody  Host 
 
Dilution  Company / Catalogue number 
 
Primary antibodies 
 
   
LLH1 (Plod1) 
 
Goat 1:200 Santa Cruz Biotech / sc-50062 
LLH2 (Plod2) 
 
Goat 1:200 Santa Cruz Biotech / sc-50067 
Plod3 
 
Rabbit 1:200 Protein Tech group / 11027-1-AP 
TGase1 (Tgm1) 
 
Goat 1:200 Santa Cruz Biotech / sc-18127 
Anti-Transglutaminase Type II 
(Tgm2) 
 
Goat 
 
1:1000 Upstate / 06-471 
α-tubulin Rabbit 1:2500 Santa Cruz Biotech / sc-5286 
 
 
Secondary antibodies 
Donkey anti-goat-HRP*-cong.  1:1000 Santa Cruz Biotech / sc-50062 
Goat anti rabbit-HRP-cong.  1:3000 Pierce / 31460 
* HRP = Horseradish peroxidase      
  
 
This incubation was performed either at room temperature for 1 h or overnight at       
4 °C. Antibodies and blocking solution were discarded and membranes were rinsed 
in washing buffer (1× PBS, 0.1% (vol/vol) Tween-20) 3×10 min, each time 
exchanging the buffer. This was followed by (depending on the host of the primary 
antibody) the application of goat or rabbit secondary horseradish peroxidase (HRP)-
conjugated antibody (Table 10) in a dilution of 1:1000 or 1:3000 at room temperature 
for 1 h. Thereafter, membranes were again rinsed in washing buffer, this time      
5×10 min each, using fresh washing buffer for every cycle. Membranes were then 
wetted with a mixture containing a 1:1 amount of peroxidase- and light sensitive 
enhancer-solution. The luminescence of the antibody-linked peroxidase reaction was 
documented on hyperfilm ECL (Kodak) in a darkroom.  
- 38 - 
The same membrane could be re-used for assessment of the expression of other 
proteins: For this purpose, the membrane was placed into washing buffer (1×5 min). 
Then the proteins were stripped off the membrane by placing the membrane in 
stripping buffer (100 mM β-mercaptoethanol, 62.5 mM Tris-Cl pH 6.8, 2% (mass/vol) 
SDS) at 50 °C for 30 min. Thereupon, the membrane was washed in washing buffer 
(2×5 min) and then blocked in blocking buffer for 1 h. The membrane could now be 
re-used for the detection of proteins.  
 
 
3.2.10 Immunohistochemistry 
Expression and location of Plod and Tgm protein and the γ-glutamyl-ε-lysine 
crosslink was assessed on 3-µm tissue sections, prepared as described above 
(Processing of lung tissue). Immunohistochemical analysis was performed using a 
Histostain-SP Kit. The whole-lung sections were deparaffinized by placing them in 
xylene 3×10 min. After that, sections were dehydrated in 100% ethanol 2×5 min, 95% 
ethanol 2×5 min, 70% ethanol 2×5 min, and 1×PBS 2×5 min. After antigen retrieval, 
performed by incubating the slides for 20 min at 100 °C in a pressure cooker in      
6.5 mM sodium citrate, pH 6.0, the endogenous peroxidase activity was quenched 
with 3% (vol/vol) H2O2 for 10 min. The sections were blocked for 10 min at room 
temperature using a blocking solution provided in the kit. After that, the primary 
antibodies (Table 11) were applied to the sections and incubated overnight at 4 °C. 
The primary antibody concentration varied depending on the type of antibody that 
was employed (Table 11). On the sections that served as negative control, no 
primary antibody was introduced, and sections were solely incubated with Tris buffer 
(“no primary” control), unless a competing peptide or protein was available, which 
was the case for Plod1, Plod3, and Tgm1 (Table 11). The next day, before applying 
the secondary antibodies (Table 11) to the sections, the slides were washed in 1× 
PBS 2×5 min. The sections were then incubated with a biotinylated secondary 
antibody for 10 min. The secondary antibody-solution was then removed and the 
slides were washed in 1× PBS 2×5 min. Streptavidin-conjugated HRP was applied to 
the sections for 10 min followed by chromogenic substrate for 1-10 min. After that, 
slides were rinsed again in 1× PBS for 2 min followed by counterstaining with 
Mayer’s hematoxylin. Staining of the sections was examined and photographed 
under an Olympus BX51 microscope. 
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Table 11: Primary and secondary antibodies used in immunohistochemistry. 
 
Antibody  Host 
 
Dilution  Company/ 
Catalogue number 
 
Primary antibodies 
 
   
LLH1 (Plod1) Goat 1:10 Santa Cruz Biotech/ 
sc-50062 
LLH2 (Plod2) Goat 1:25 Santa Cruz Biotech/ 
sc-50067 
Antibody to PLOD3 Rabbit 1:25 Proteintech Group, Inc/ 
11027-1-AP 
TGase1 (Tgm1) Goat 1:15 Santa Cruz Biotech/ 
sc-18127 
Anti-Transglutaminase Type II 
(Tgm2) 
Goat 1:50 Upstate/  
06-471 
N-ε-γ-glutamyl Lysine  Mouse 1:100 Abcam/ 
Ab424 
 
Secondary antibodies 
 
   
Biotinylated antibody to mouse  Ready-To-Use Invitrogen/ 
95-6543B 
Biotinylated antibody to rabbit  Ready-To-Use Invitrogen/ 
95-6143B 
Biotin-XX rabbit anti-goat-IgG  1:1000 Invitrogen/ 
A10518 
 
Competing peptides/proteins 
 
   
Plod1 peptide   Santa Cruz Biotech/ 
SC-50062P 
Plod3 GST-fusion   Proteintech Group, Inc/ 
Ag1480 
Tgm1 peptide   Santa Cruz Biotech/ 
SC-18127P 
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Chapter 4 
 
Results 
4.1 Expression of lysyl hydroxylases and transglutaminases is 
dysregulated by hyperoxia in vivo 
Neonatal mice that breathed 85% oxygen demonstrated an up-regulation of ECM 
cross-linking enzyme mRNA levels (Fig. 6) in lung tissues. Gene (mRNA) expression 
levels were assessed by semi-quantitative PCR and exhibited elevated levels for 
Plod1 (Fig. 6A) starting after 7 to 14 days of postnatal hyperoxia exposure. Similarly, 
Plod2 mRNA levels (Fig. 6A) were up-regulated from P14, while Plod3 mRNA levels 
(Fig. 6A) were evenly expressed throughout the observed time-period with a slight 
signal enhancement after 28 days of exposure to hyperoxia. Transglutaminase 1 
(Fig. 6B) demonstrated a clear increase in gene-expression from P14 onward. As 
expected, since Tgm2 is a marker for lung maturation, mRNA levels of Tgm2 (Fig. 
6B) increased with postnatal age. However, except for a subtle signal enhancement 
at P7, effects of hyperoxia on Tgm2 gene expression were not evident. 
Protein-expression in mouse lung tissue was assessed by western blot (Fig. 7). 
Assessment of Plod1 protein expression (Fig. 7A), confirmed the pattern seen in 
mRNA expression and, exhibited increased signals at P21 and P28 in tissues from 
hyperoxia-exposed pups compared to tissues from control pups maintained for the 
same period of time under normoxic conditions. Plod2 exhibited increased protein 
abundance throughout the first 28 days of life under hyperoxia (Fig. 7A). The Plod3 
protein abundance (Fig. 7A) was slightly elevated over the first two weeks under 
hyperoxic conditions, but at P28 was a down-regulated compared to the room-air 
control pups. A similar tendency could be seen in the protein expression levels of 
Tgm1 (Fig. 7B): up-regulation in the early stages (P7-P14) and slight down-regulation 
towards adulthood (P28). These trends are not consistent with the gene expression 
findings. It is noteworthy that the so-called keratinocyte transglutaminase (Tgm1) is 
expressed in the lung. Transglutaminase 2 (Fig. 7B) protein was expressed from two 
alternatively-spliced mRNA species. Although no effect of hyperoxia on mRNA levels 
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was observed, the Tgm2 protein was more abundant in hyperoxia-exposed lungs. 
While the reason for this is not immediately apparent, it may well be that hyperoxia 
can stabilise Tgm2 protein, resulting in an increased abundance.  
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Figure 6. Gene expression profiles for (A) lysyl hydroxylases (Plod1, Plod2, Plod3) and (B) 
transglutaminases (Tgm1, Tgm2). The mRNA from the lungs of mouse pups exposed to  
21% O2 or 85% O2 was monitored by semi-quantitative reverse transcriptase-polymerase 
chain reaction over the first month of postnatal life. The constitutively-expressed Hspa8 gene 
served as a control for loading equivalence. 
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Figure 7. Protein expression of (A) lysyl hydroxylases (Plod1, Plod2, Plod3) and (B) 
transglutaminases (Tgm1, Tgm2) in mouse lung tissue was monitored by immunoblot 
analysis between postnatal day 1 and 28 (P1, P7, P14, P21, P28). Lungs were harvested 
from mice breathing 21% or 85% O2. The constitutively-expressed α-tubulin was used as a 
loading control. 
 
 
 
4.2 Inducibility of Plod- and Tgm-expression by hyperoxia 
and/or TGF-β-stimulation in different cell types 
In order to locate where exactly in the lung the dysregulation of Plod and Tgm 
expression took place, it was necessary to examine specific cell lines. Moreover, the 
response of the cell lines to hyperoxia and TGF-β was assessed. Mouse lung 
fibroblasts (NIH/3T3), human keratinocytes (HaCaT) and human paSMC mRNA were 
monitored by semiquantitative PCR for changes in Plod and Tgm gene expression 
after having stimulated the cells with either 85% O2 and TGF-β, separated or together 
for 24 h (Fig. 8). The Plod gene expression (Fig. 8A) was evident in all three cell 
lines, but was not altered by TGF-β and/or hyperoxia exposure except for Plod2 
mRNA levels, which were slightly elevated in keratinocytes after TGF-β stimulation. 
However, no differences were evident when cells were treated with TGF-β and    
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Tgm1 
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85% O2 or with TGF-β alone. As expected, Plod2 presented as two          
alternatively-spliced isoforms after transcription, evident as a double-band by semi-
quantitative RT-PCR. However, this only occurred in human keratinocytes and has 
not been described before. Up to now, the appearance of both splice-isoforms has 
only been described in human kidney, spleen, liver and placenta.  
Transglutaminase 2 mRNA expression (Fig. 8B) was also, but more markedly, up-
regulated after one day of TGF-β treatment in keratinocytes and, again, exhibited no 
dysregulation caused by hyperoxic conditions. No changes could be seen in Tgm1 
gene-expression, which was only present in keratinocytes. Transglutaminase 1, also 
known as the keratinocyte transglutaminase, is a cell-specific enzyme. In order to 
study the effects on a cell-line that definitely contains Tgm1, keratinocytes, although 
not typically lung cells, were also investigated. The analysis of the mouse whole-lung 
tissue demonstrated that Tgm1 is present in the lung. The analysis of the cell-lines 
demonstrated that Tgm1 is neither present in mouse fibroblasts nor paSMC. This 
raises the question whether keratinocytes are actually present in the lung or whether 
there is a different cell type, which was not investigated here, that expresses Tgm1. 
As mentioned already in the Introduction, Tgm1 has been described in normal 
bronchial epithelium. These cells should be investigated concerning Tgm1 
expression under hyperoxia and TGF-β influence.  As described in Materials and 
Methods TGM2 has two different reverse primers in human cells, hence, there is 
TGM2a and TGM2b. Interestingly, no TGM2b expression is found in human paSMC. 
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Figure 8. Different cell types were treated with either TGF-β1, hyperoxia or both for 24 h. 
Expression of (A) lysyl hydroxylases (Plod1, Plod2, Plod3) and (B) transglutaminases (Tgm1 
and Tgm2) mRNA was then monitored by semiquantitative reverse transcriptase-polymerase 
chain reaction. The lane on the right of each gene was filled with cDNA from whole lung 
tissue and was used as an expression control (c). The Hspa8 gene served as loading 
control. 
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4.3 Localization of lysyl hydroxylases and transglutaminases 
in lung tissue of newborn mice 
Localization of lysyl hydroxylases, transglutaminases and the γ-glutamyl-ε-lysine 
cross-link in the lungs of mouse pups was assessed by immunohistochemistry (IHC). 
Lung tissue was harvested from newborn mice at different postnatal days. Lysyl 
hydroxylase was detected in mouse lung tissue at P28 (Plod1) and P7 (Plod2 and 
Plod3) (Fig. 1). Transglutaminases were assessed in mouse lung tissue at P7 (Tgm1) 
and P14 (Tgm2) (Fig. 2). The enzymes were assessed in tissue at a postnatal age 
that was most appropriate (based on immunoblot analyses) to demonstrate 
differences in the intensity of staining between hyperoxia- versus normoxia-exposed 
lungs. However, here, IHC was primarily done to determine the exact location of 
Plods and Tgms in lung tissue, as this technique is generally not suitable to quantify 
protein expression. 
Plod1 demonstrated a cell-specific expression pattern in the lung tissue of newborn 
mice: At P28 Plod1 was mainly localized in the walls of the pulmonary vessels. With 
regard to the results of the mRNA expression analysis in the cell lines, one would 
expect a more broad localization. This may be explained by the timepoint of 
assessment, as towards adulthood the distribution profiles of Plods become more 
specialized. Earlier in development, at P7 (data not shown), staining was also evident 
in the septa. Moreover, staining at P7 was more pronounced under normoxia than 
under hyperoxia, as indicated by gel PCR and western blot. However, it must be kept 
in mind that IHC is not a quantitative technique. The staining at P28, in contrast, was 
accentuated in the tissue that was exposed to chronic hyperoxia which, again, is 
consistent with the findings from the semiquantitative PCR and the western blots. 
Plod2, protein expression of which was demonstrated to be up-regulated by 
hyperoxia throughout the first postnatal month, was examined for tissue localization 
at P7. Localization was mainly limited to the septa. Moreover, very little staining could 
be observed in paSMC and airway muscle (not shown). Again staining was more 
pronounced in tissue under chronic hyperoxia. 
Plod3 was studied in tissues at P7 and was located very specifically at the septal 
junctions. This confirms earlier findings, that described pulmonary Plod3 as being cell 
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specific for type II pneumocytes. As expected, elevated O2 levels did not obviously 
influence Plod3 expression.  
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Figure 9. Localization of lysyl hydroxylases in lung tissue of newborn mice exposed to either 
hyperoxia (85% O2) or normoxia (21% O2). Sections were prepared from mouse lungs at P28 
(Plod1) and P7 (Plod2 and Plod3) and assessed for localization of the respective enzyme. 
Control sections were solely incubated with Tris buffer. 
 
 
The staining of Tgm1 was of particular interest as the enzyme has been described in 
lung tissue previously and, in the present study, was detected in the whole lung 
tissue of mice by RT-PCR and western blot, but was found in neither mouse lung 
fibroblasts nor paSMC. Here, the IHC revealed strong staining only at the junctions of 
the alveolar septa near the type II pneumocytes. If at all, there was faint staining in 
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Plod2 
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the bronchial epithelium. The sections were taken from mice at P7, as in the western 
blot analysis dysregulation by hyperoxia was most evident at that time-point. Again, 
this was reproducible by IHC, where the staining appeared more pronounced under 
hyperoxia. 
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Figure 10. Localization of transglutaminases and the γ-glutamyl-ε-lysine cross-link in lung 
tissue of newborn mice exposed to either hyperoxia (85% O2) or normoxia (21% O2). 
Sections were prepared from mouse lungs at P7 (Tgm1), P14 (Tgm2) and P7 (cross-link) 
and assessed for localization of the respective enzyme. Control sections were solely 
incubated with Tris buffer.  
 
Sections for Tgm2 staining were obtained from pups at P14 and demonstrated 
overall stronger staining in lung tissue that was exposed to hyperoxia. 
Transglutaminase 2 was mainly localized in alveolar septa and vascular endothelial 
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cells. There was also faint staining noted in the bronchial epithelium. In contrast to 
the paSMC in vitro data, paSMC were, if at all, very weakly stained. 
Staining for the γ-glutamyl-ε-lysine cross-link was assessed at P7. The localization of 
this product of the Tgm-catalyzed reaction, which is highly resistant to proteolysis, 
may hint towards important conclusions about the pathomechanism of the disturbed 
septation in BPD. Consistent with the location of the Tgms, the cross-link was found 
in the junctions of the alveolar septa close to the type II pneumocytes. Increased 
cross-linking of the pulmonary type I and type III collagen at these locations, which 
are crucial for the development of the blood-air barrier, may lead to the characteristic 
disturbance of septation and lung function in BPD. However, a clear increase in 
staining intensity in lung tissue exposed to hyperoxia versus tissue exposed to 
normoxia could not be seen at P7. As IHC is not a quantitative technique, this should 
not be overinterpreted. 
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Chapter 5 
 
Discussion 
Proper branching of the airways and secondary septation are crucial for normal lung 
development, as these processes occur mainly during late lung development and are 
highly dependent on proper ECM production and remodeling74. In important 
developmental lung diseases such as BPD, ECM remodeling and deposition have 
been demonstrated to be disturbed. The exact pathogenic mechanisms, however, 
remain poorly understood. While several studies performed to date have focused on 
the production of ECM proteins in BPD, few have addressed the subsequent 
remodeling of these proteins. The dynamics of ECM remodeling is impacted by the 
establishment and breakdown of the intra- and inter-molecular cross-links of the ECM 
proteins. Enzymes that cross-link ECM proteins have been identified previously and 
the expression of these enzymes has been demonstrated to be dysregulated in 
animal models of BPD75. However, there have been inconsistent findings reported 
previously regarding the regulation of ECM cross-linking enzymes by hyperoxia: 
Lysyl oxidase eypression was down-regulated in a rat model of BPD76, using 95% O2 
to create hyperoxic conditions, whereas lysyl oxidase expression was up-regulated in 
a mouse model of chronic exposure to hyperoxia of 85% O2
38.This divergence may 
be explained by different oxygen-concentrations used in the two animal models, or by 
the differing response to high oxygen concentrations displayed by mammals, even 
between different mouse strains77. 
In this study, two families of enzymes that are known to be important for ECM 
stability were assessed with respect to responses to hyperoxia, using a mouse model 
of BPD: the lysyl hydroxylases (Plod1, Plod2, Plod3) and the transglutaminases 
(Tgm1, Tgm2). So far, Plods and Tgms have not been examined concerning their 
role in the pathogenesis of BPD. With reference to the trend-setting studies 
mentioned above that suggest dysregulation of ECM crosslinking enzymes, in this 
study it was hypothesized that Plod and Tgm expression is also dysregulated in BPD. 
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The data presented here demonstrate the up-regulation of expression of three 
collagen cross-linking enzymes (Plod1, Plod2, Tgm1) at the mRNA level and the    
up-regulation of expression of three enzymes (Plod1, Plod2, Tgm2) at the protein 
level in newborn animals with hyperoxic lung injury and perturbed ECM structure. 
Although the up-regulation at the gene and protein levels under hyperoxic conditions 
are not completely consistent with each other, the trend that can be seen supports 
the hypothesis of the “over-stabilized” ECM in BPD. The expression of the lysyl 
hydroxylases Plod1 and Plod2 are up-regulated consistently at the mRNA level as 
well as at the protein level by chronic hyperoxia. Transglutaminase 1 expression, 
however, was up-regulated by hyperoxia at the gene expression level, but not at the 
protein expression level, whereas Tgm2 expression was up-regulated at the    
protein-level by hyperoxia, but not at the gene-level. The reason for this divergence is 
not completely clear, but may be explained by additional control mechanisms before 
or after translation. With regard to the pathogenesis of BPD, the protein levels of the 
ECM cross-linking enzymes, as they reflect the regulation of the executive enzymes, 
have a higher importance than the gene expression levels.  
The localization of the Plods, Tgms and the the γ-glutamyl-ε-lysine cross-link was 
assessed in lung tissue from newborn pups by IHC. This experiment was carried out 
to detect the location in the lung where the hypothesized pathological cross-linking 
occurs. Time points of assessment were chosen according to when the clearest 
changes of protein production were evident in the western blot analysis. Intensity of 
staining was, except for the cross-link and Plod3, always increased by hyperoxia. 
This is consistent with the results from the western blots. However, as IHC is not a 
quantitative technique and it should not be used as such. All proteins were localized 
in the septa, which supports the hypothetical role of these enzymes in the 
pathomechanism of disturbed septation in BPD.  
Up-regulation of expression of enzymes of the Plod family, which are broadly and 
highly expressed during lung development, may lead to extensive consequences for 
ECM assembly of the immature lung. Increased Plod1 levels may lead to an 
increased hydroxylysine/lysine ratio in the helical collagen structure and may explain 
the “tortuous” appearance of the collagen fibers that was observed in infants with 
chronic lung disease37. The consequences of alterations to lysyl hydroxylase 
abundance can be well observed in Plod1-/- mice that demonstrate decreased 
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hydroxylysine content in all tissues, degenerated smooth muscle cells, and abnormal 
collagen morphology78. The main cause of death in these mice was aortic aneurysms 
due to gradual deterioration of the aortic wall, as observed by ultra-structural 
analysis. These data suggest a key role for this family of enzymes in the 
development of the ECM. However, an analysis of pulmonary ECM in these mice 
was not performed. 
In 2003 a study from van der Slot et al. demonstrated that the collagen deposited in 
fibrotic tissue contained increased levels of Plod2 mRNA and of the pyridinoline 
cross-link, which derives from hydroxylated lysine residues. By analyzing the genetic 
defect of Bruck’s syndrome, which is charcterized by pyridinoline deficiency, it could 
be concluded that the pyridinoline cross link is the result of Plod2 enzyme activity. 
Hence, it was postulated that elevated Plod2 levels are, at least in part, responsible 
for tissue fibrosis79. Additionally, two years later, a study demonstrated that the 
profibrotic Plod2b as well as the pyridinoline cross-link are induced by various 
cytokines including all three isoforms of TGF-β, IL-4, activin A, and tumor necrosis 
factor (TNF)-α in normal skin fibroblasts56. Given these results, pulmonary Plod2b 
upregulation, as seen in the present study, may lead to fibrotic changes in collagen 
deposition and remodeling in the lung as a result of increased TGF-β signaling under 
chronic hyperoxia. However, Plod2 mRNA expression was not enhanced in mouse 
lung fibroblasts and human paSMC after one day of TGF-β1 stimulation. This may be 
due to insufficient stimulation time, which was limited by the survival time of the cells. 
However, a slight upregulation of Plod2 mRNA levels could be seen in human 
keratinocytes. The assessment of keratinocytes was performed as a control and 
would only be of interest regarding BPD, if keratinocytes were present in the lung. 
Transglutaminase1, although primarily known to be present in keratinocytes, has 
been described to be expressed in the bronchial epithelium61. The IHC in the present 
study, however, demonstrates a specific Tgm1 presence in the septal junctions 
around the type II pneumocytes and only weak staining in the bronchial epithelium. 
Presence of Tgm1 in pneumocytes has not been described before and should be 
examined more closely in pneumocyte cell lines. The crosslink built by Tgm1 activity 
is highly resistant to proteolysis and, if prematurely up-regulated in the lung within the 
first two postnatal weeks under chronic hyperoxia, as seen in the immunoblot 
analysis, may lead to irreversible damage to normal pulmonary development. This 
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mechanism, however, is highly speculative, as, to date, there is very little known 
about the role of pulmonary Tgm1.  
Transglutaminase 2, in contrast, has been extensively examined in the lung and is 
known to have profibrotic activity in the lung. The latest publication on this topic 
demonstrated Tgm2 involvement in pulmonary fibrosis in a mouse model, the 
importance of Tgm2 for normal lung fibroblast function, and Tgm2 inducibilty by  
TGF-β80. The early and constant up-regulation of Tgm2 by chronic hyperoxia may, 
hence, lead to early, excessive scar tissue formation by irreversible ECM 
crosslinking. Taking into consideration that Tgm2 can be used as a marker for lung 
development81, this may be interpreted as an early arrest of lung maturarion through 
oxygen-toxicity.  Definite enhancement of Tgm2 mRNA expression can be seen after 
one day of TGF-β1 stimulation in human keratinocytes, but neither in human paSMC 
nor in mouse lung fibroblasts. This should be re-examined after longer exposure 
periods to TGF-β1 and in other pulmonary cell lines. 
 
5.1 Conclusion 
These data demonstrate two more families of dysregulated ECM crosslinking 
enzymes (in addition to lysyl oxidases) in a mouse model of BPD. The up-regulation 
of Plod and Tgm expression under chronic normobaric hyperoxia supports the 
hypothesis of a pathological “over-stabilization” of the ECM in BPD. However, more 
data need to be gathered regarding Plod and Tgm function in BPD.  
Regarding the cytokine inducibility of Plods and Tgms, more experiments are needed 
in order to draw accurate conclusions: Apart from TGF-β1, more cytokines should be 
targeted, including for example IL-4, activin A, TNF-α and the other TGF-β subtypes. 
Other promising pulmonary cell lines could be examined regarding their cytokine 
inducibility, including bronchial epithelial cells, pneumocytes and vascular endothelial 
cells. Promoter-inducibility of the enzymes could be assessed by luciferase essay. In 
2007, a study showed improved pulmonary alveologenesis and vasculogenesis in 
anti-TGF-β IgG1 antibody treated mice exposed to chronic hyperoxia40. Apart from 
being a possible treatment option in the future, these antibodies could be used to 
indirectly prove inducibility of Plods and Tgms: Antibody-treated mice should show 
decreased levels of Plod and Tgm expressions, if they are TGF-β inducible.  
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In summary, these two families of ECM enzymes that might play an important role in 
the pathogenesis of BPD provide more targets for further investigation and 
encourage looking for other dysregulated ECM cross linking families.  
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Chapter 6 
 
Abstract 
Bronchopulmonary dysplasia is a complication of premature birth characterized by 
impaired alveolar development. Remodeling of the ECM is a driving force for 
alveolarization and, if pertubated, may impair septation, suggesting dysregulation of 
ECM remodeling enzymes that drive collagen fiber formation and maturation: the 
procollagen-lysine, 2-oxoglutarate 5-dioxygenases (Plod) family, also known as lysyl 
hydroxylases (which catalyzes glycosylation and hydroxylation of collagen), and the 
transglutaminases Tgm1 and Tgm2, which cross-link ECM components.  
Expressions of Plod1, Plod2, Plod3, Tgm1 and Tgm2 were determined using a 
popular mouse model of BPD, in which mouse pups are exposed to hyperoxia (85% 
O2) or normoxia (21% O2) for 28 days after birth. The lungs of these mice were 
harvested at various time-points and assessed for Plod and Tgm expression and 
localization by semi-quantitative RT-PCR, immunoblotting and immunohisto-
chemistry. Increased expressions of Plods and Tgms could be observed at the gene 
and protein levels under hyperoxic conditions compared to normoxic conditions. 
The data suggest that BPD is characterized by elevated levels of ECM-stabilizing 
molecules, which may make the ECM more resistant to remodeling. This over-
stabilized state of the ECM may, at least in part, underlie the arrested septation 
observed both in the lungs of infants with BPD, and in animal models of BPD. 
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Chapter 7 
 
Zusammenfassung 
Bronchopulmonale Dysplasie ist eine Komplikation bei Frühgeborenen, welche durch 
eine fehlgesteuerte Entwicklung der Lungenalveolen charakterisiert ist. Der Umbau 
der ECM ist die treibende Kraft für die Bildung der Alveolen und kann, falls er 
behindert wird, zu einer Beeinträchtigung der alveolären Septierung führen. Dies 
lässt auf eine Fehlregulation der für den Umbau der ECM verantwortlichen Enzyme 
bei der Entstehung der BPD schließen: Die Prokollagen-Lysin, 2-Oxoglutarat 5-
Dioxygenase (Plod) Familie, auch bekannt als Lysyl Hydroxylasen (welche die 
Glykosylierung und Hydroxylierung von Kollagenmolekülen katalysieren) und die 
Transglutaminasen Tgm1 und Tgm2, welche die ECM Komponenten quervernetzen.  
Um die Expression von Plod1, Plod2, Plod3, Tgm1 und Tgm2 zu untersuchen, wurde 
ein gängiges Maus-Modell der BPD benutzt, bei dem neugeborene Mäuse in den 
ersten 28 postnatalen Tagen entweder hohen Sauerstoff-Konzentrationen (85% O2) 
oder normalen Sauerstoff-Konzentrationen (21% O2) ausgesetzt wurden. Die Lungen 
dieser Mäuse wurden zu verschiedenen Zeitpunkten entnommen und mittels 
semiquantitativer RT-PCR, Western-Blot und Immunhistochemie  hinsichtlich der 
Plod- und Tgm-Expression und -Lokalisation untersucht.  
Unter dem Einfluss von hohen Sauerstoffkonzentrationen konnte eine Steigerung der 
Plod- und Tgm-Expression sowohl auf Gen- als auch auf Proteinebene beobachtet 
werden, verglichen mit der Expression in der Kontrolle unter normalen 
Sauerstoffkonzentrationen. 
Diese Daten deuten darauf hin, dass BPD durch eine gesteigerte Synthese von 
ECM-stabilisierenden Enzymen gekennzeichnet ist, was möglicherweise zu einer 
Behinderung des notwendigen Umbaus der ECM führt. Dieser „über-stabilisierte“ 
Zustand könnte, zumindest teilweise, der frühzeitigen Terminierung der alveolären 
Septierung zu Grunde liegen, welche sowohl in den Lungen der an BPD 
verstorbenen Kinder, als auch in BPD Tiermodellen beobachtet wurde.  
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